• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Wright Medical launches long-term study for Infinity total ankle

Wright Medical launches long-term study for Infinity total ankle

October 31, 2017 By Brad Perriello

Wright MedicalWright Medical (NSDQ:WMGI) said today that it launched a long-term study of the Infinity total ankle replacement device it introduced three years ago.

The 10-year follow-up study of 200 patients aims to evaluate survivorship and to characterize improvements in patient-reported outcomes, Memphis-based Wright said.

At its June 2014 debut, the company touted Infinity as a solution for both primary ankle arthroplasties and secondary or revision surgeries. The device is designed to be compatible with Wright’s Inbone II talar components and the Prophecy pre-operative alignment system.

“With the growing popularity and increasing demand for alternatives to ankle fusion, there is a real need for quality, forward-looking studies that document the results of total ankle replacement surgery to further validate our clinical decision making,” primary investigator Dr. Andrew Murphy, of the Campbell Clinic in Memphis, said in prepared remarks. “Wright Medical is leading the way in this progress, and we expect to glean valuable data from this study of the Infinity total ankle system.”

Wright also said the 500-patient post-market study in the U.K. it launched last year, also designed to evaluate 10-year survivorship and patient-reported outcomes, enrolled 100 patients as of the third quarter.

“It is increasingly important for industry and clinicians to work together to provide patients, colleagues and healthcare providers with robust clinical evidence to support new systems,” added chief investigator Dr. David Townshend of the Northumbria NHS Healthcare Trust. “We are delighted that Wright has taken the opportunity to sponsor a high-quality, multi-center follow-up study in the United Kingdom to evaluate the Infinity total ankle replacement, and we look forward to sharing these results.”

“The undertaking of both the US and UK post-market clinical studies are a testament to Wright’s ongoing commitment to foot and ankle surgeons and their patients,” global clinical affairs VP Ann Burgess said. “By collecting longitudinal patient outcomes through real-world experience of non-design surgeons at centers of excellence around the globe, Wright will generate important information that will drive the continued evolution of the treatment and technologies addressing end-stage ankle arthritis for years to come.”

Filed Under: Clinical Trials, Orthopedics Tagged With: wrightmedical

More recent news

  • Neuralink files to raise $649M in new equity offering
  • BofA: Surgical robot remanufacturing not a major setback for Intuitive
  • InspireMD wins CE Mark approval for CGuard Prime
  • Philips reports first cases for VeriSight Pro 3D ICE catheter in Europe
  • Ceryx Medical raises $15M to support bioelectronic pacemaker

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy